Ms. Donley brings a unique combination of business and legal experience to Stemina. She has more than twenty years of experience in intellectual property, law, and business management. Ms. Donley served as General Counsel and Director of Business Development for the Wisconsin Alumni Research Foundation (WARF) for more than eight years.
During those eight years, Ms. Donley negotiated hundreds of licenses and sponsored research and collaboration agreements between industry and WARF, the intellectual property management organization for the University of Wisconsin. Ms. Donley also served as Managing Director of both WARF subsidiaries: WiSys Technology Foundation (WiSys) and WiCell Research Institute (WiCell).
WiCell distributes human embryonic stem (hES) cells, trains researchers worldwide and conducts important research involving many aspects of hES cell research. In 2005, WiCell was awarded a $16 million contract by the National Institute of Health to serve as the National Stem Cell Bank.
Prior to joining WARF in 1998, Ms. Donley practiced law with the law firm of Quarles & Brady in the areas of intellectual property law, business transactions, securities, and corporate law.
Elizabeth LR Donley, JD MBA MS
Chief Executive Officer
View more >>
Dr. Burrier is a career technology executive with experience in pharmaceutical research, ‘biosupplier’ product development, and biotech services. While working in pharma, he participated and led programs resulting in drugs currently on the market including Zetia, Vytorin, and others.
He is very experienced in assays and paradigms used for drug discovery having participated in over 150 drug discovery programs while working for Schering-Plough, Eli Lilly, GelTex, and Genzyme. In the biosupplier arena, Dr. Burrier led teams to innovate on an ongoing basis in the areas of cell biology, cell media development, assay development, and workflow improvements with companies including Invitrogen, and EMD Millipore (Merck). The markets around which these programs were based include academic and industrial cell biology research, stem cells, and regenerative medicine, as well as biotherapeutic protein production.
Dr. Burrier joined Stemina to bring his expertise of cell biology, assay development, scientific operations, program management, and organizational effectiveness to facilitate success and to continue to fulfill his interest of continually improving human health.
Robert E. Burrier, PhD
Chief Operating Officer and Vice President of Research and Development
View more >>
Dr. Alan Smith is the Associate Director of Bioinformatics at Stemina Biomarker Discovery. His current research involves the development of computational procedures and experimental designs for identification of predictive metabolic signatures for applications in predictive toxicology and clinical diagnostics.
Dr. Smith developed Stemina Biomarker Discovery’s non-targeted discovery metabolomics pipeline that incorporates a unique array of proprietary data processing algorithms. He has utilized the metabolomics platform to create predictive metabolic models of developmental toxicity utilizing human pluripotent stem cells, cardiotoxicity in induced pluripotent stem cell derived cardiomyocytes, and identified biomarkers related to metabolic subtypes of autism spectrum disorder.
Dr. Smith completed his Bachelor’s and Master’s Degrees in Biology at Indiana University-Purdue University Fort Wayne and received his Ph.D. from the University of Wisconsin-Madison in Plant Breeding and Plant Genetics.
Alan M. Smith, PhD
Associate Director of Computational Biology
View more >>